https://www.selleckchem.com/pr....oducts/vx803-m4344.h
Aim Eltrombopag and romiplostim are US FDA approved for treatment of immune thrombocytopenia in patients with insufficient response to other treatments. Clinical or real-world data comparing outcomes of the two drugs are limited. Methods This retrospective cross-sectional study sought information on bleeding-related episodes (BREs), adverse events (AEs) and other outcomes of eltrombopag or romiplostim treatment in immune thrombocytopenia. Results Patients receiving eltrombopag experienced significantly reduced BREs, severe BREs, res
Like
Comment
Share
